Clinical Trials Logo

Clinical Trial Summary

A sufficient number of subjects will be entered into testing to complete 42 subjects per each of the 2 test and 2 control configurations. A total of 84 subjects, testing bi-laterally (168 abdomen and groin sites in total completed, 42 abdomen and groin sites per each test and control material) will be evaluated using the standardized ASTM E1173 test method. Following a 14-day restriction period, subjects will be sampled for baseline, 10 minutes, 6 hours, and 24 hours post application (subjects will not be sequestered) for microbial reduction evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and groin: ≥ 5.0 log10 CFU/cm2.


Clinical Trial Description

At least 84 subjects will be treated bilaterally with two of the four test materials (Test Product #1, Test Product #2, Positive Control, and Negative Control), one per each side of the abdomen and inguinal test sites. Subjects will be required to complete a 14-day pretest conditioning period. Subjects will complete a 2-day test period, during which time subjects' sites will be treated with the test materials and samples taken following treatment. The Cylinder Sampling Technique will be performed for baseline and for sampling 10-minutes, 6-hours, and 24-hours post-test material-application on Test Days. The effectiveness criteria are that the log10 recoveries of the two test products (1% and 1.5%) are non-inferior to the Positive Control (2.0% chlorhexidine gluconate) with a 0.5 margin (log10 scale) per square centimeter on the abdominal and inguinal sites within 10 minutes after drying. The determination of non-inferiority will be based on the upper bounds of the 95% confidence interval being equal to or less than 0.5. Superiority will not be evaluated in this study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04703335
Study type Interventional
Source Zaycor Healthcare Corp
Contact Jose Zayas, PhD
Phone 13058984868
Email jzayas@zaycor.com
Status Not yet recruiting
Phase Early Phase 1
Start date June 1, 2023
Completion date September 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05568953 - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Phase 2
Completed NCT04568889 - Minnesota COVID-19 Testing Project N/A
Completed NCT06063330 - Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects Phase 1
Completed NCT01198925 - Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion Phase 4
Completed NCT05063812 - Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
Not yet recruiting NCT03636711 - Antibiotic Stewardship in Infectious Disease Departement
Completed NCT03457688 - Effect of Prebiotic Fructans to Reduce Number of Febrile Infections in Children N/A
Completed NCT03241355 - Prebiotic Fructans on the Incidence of Acute Infectious Diseases in Children N/A
Terminated NCT05420077 - Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273 Phase 1
Completed NCT04084106 - Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota Phase 4
Recruiting NCT05013944 - AnovaOS Network Powered Patient Registry
Completed NCT03893279 - Perception of Smell and Taste During Antibiotic Treatment
Active, not recruiting NCT05619770 - Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects Phase 1
Completed NCT01772901 - Brief Influenza Vaccine Education to Pregnant Women N/A
Completed NCT05413772 - Temocillin in ESBL-Enterobacteriaceae Infections
Completed NCT04319328 - Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
Completed NCT04613271 - Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia Phase 3
Completed NCT03239665 - Vaccination Education Through Pharmacists and Senior Centers (VEPSC) N/A
Completed NCT03224026 - Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without Source
Not yet recruiting NCT06102070 - Genetic Susceptibility to Severe Infections